TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2479963

Group type: EXPERIMENTAL
Intervention: Immediate combination chemotherapy and radiotherapy
Number of subjects: 151

Group type: COMPARATOR
Intervention: Selective treatment (chemotherapy and/or radiotherapy as needed)
Number of subjects: 151
Study: 781336

Group type: EXPERIMENTAL
Intervention: Kaolin‐pectin suspension concentrate (Kao‐Con)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diphenoxylate‐atropine liquid (Lomotil)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Kaolin suspension
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pectin suspension
Number of subjects: 80
Study: 31280410

Group type: EXPERIMENTAL
Intervention: Normal saline (0.9% sodium chloride in 5% dextrose)
Number of subjects: 150

Group type: COMPARATOR
Intervention: N/2 saline (0.45% sodium chloride in 5% dextrose)
Number of subjects: 150
Study: 28167197

Group type: EXPERIMENTAL
Intervention: Treadmill gait training with 0% load
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Treadmill gait training with 5% load
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Treadmill gait training with 10% load
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Treadmill with 0% load)
Number of subjects: 30
Study: 25963586

Group type: EXPERIMENTAL
Intervention: EDTA conditioning (17% EDTA for 2 min prior to adhesive application)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no EDTA conditioning, placed according to manufacturer's instructions)
Number of subjects: 48
Study: 23425732

Group type: EXPERIMENTAL
Intervention: TEG‐guided prophylaxis with escalating low‐molecular weight heparin (LMWH) up to 5,000 IU twice daily with the addition of aspirin
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5,000 IU of LMWH daily (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: In vitro studies with apheresis platelets
Number of subjects: 50
Study: 22087615

Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing standardized lemon verbena extract (14% verbascoside, w/w) and fish oil omega-3 fatty acid
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 19133801

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 50
Study: 16820316

Group type: EXPERIMENTAL
Intervention: Cervical SNAGs
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 15017517

Group type: EXPERIMENTAL
Intervention: Sucralfate (2 g, 10 mL suspension, twice a day for 6 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 50
Study: 10834412

Group type: EXPERIMENTAL
Intervention: Nighttime-only insulin pump therapy
Number of subjects: 10
Study: 9076405

Group type: EXPERIMENTAL
Intervention: Plain ascorbic acid (250 mg BID)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Slow release ascorbic acid (250 mg BID)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 8364279

Group type: EXPERIMENTAL
Intervention: Diskhaler
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 20

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 20
Study: 2432041

Group type: EXPERIMENTAL
Intervention: Rheologically active substances (Dextran 40, hydroxyethyl starch 40/0.5)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Vasoactive and metabolically active substances (naftidrofurylhydrogenoxalate, Vinpocetin, betahistine, pentoxifylline, flunaricine, Regeneresen AU)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation
Number of subjects: 400
Study: 28553791

Group type: EXPERIMENTAL
Intervention: Processing speed training
Number of subjects: 2897

Group type: EXPERIMENTAL
Intervention: Reasoning training
Number of subjects: 2897

Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 2897

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 2897
Study: 26504907

Group type: COMPARATOR
Intervention: Traditional inferior alveolar nerve block (IANB)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: IANB using a computer-controlled local anesthetic delivery system (CCLAD)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intraligamental anesthesia (ILA) using CCLAD
Number of subjects: 91
Study: 23702047

Group type: COMPARATOR
Intervention: Hygiene promotion and water treatment (HP&WT) and sanitation improvements in 'water-available' schools
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hygiene promotion and water treatment (HP&WT) in 'water-available' schools
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water-supply improvement, HP&WT, and sanitation in 'water-scarce' schools
Number of subjects: 0
Study: 22836448

Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 20050880

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 600 mg intravenous treatment for 21 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17397307

Group type: EXPERIMENTAL
Intervention: Coronally positioned flap (CPF) for root exposure without NCCL (group 1)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Coronally positioned flap (CPF) with resin modified glass ionomer cement (RMGI) restoration for root exposure with NCCL (group 2)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Coronally positioned flap (CPF) with microfilled resin composite (MRC) restoration for root exposure with NCCL (group 3)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Comparison between groups 2 and 3
Number of subjects: 59
Study: 12759885

Group type: EXPERIMENTAL
Intervention: Glipizide GITS (5 mg/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 50
Study: 10950834

Group type: EXPERIMENTAL
Intervention: Epidural blockade with local anesthetic
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no epidural blockade)
Number of subjects: 16
Study: 9051543

Group type: EXPERIMENTAL
Intervention: Epidural morphine (bolus 0.015 mg/kg followed by an infusion 0.003 mg/kg/hr)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Epidural oxycodone (bolus 0.15 mg/kg followed by an infusion 0.03 mg/kg/hr)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravenous oxycodone (same dose as in the epidural group)
Number of subjects: 44
Study: 8112441

Group type: EXPERIMENTAL
Intervention: Bambuterol, 10 mg once daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Terbutaline, 5 mg controlled release twice daily
Number of subjects: 70
Study: 2877127

Group type: EXPERIMENTAL
Intervention: 60 mg indenolol once a day for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 120 mg indenolol once a day for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo during the 14 day run-in period
Number of subjects: 0
Study: 29413983

Group type: EXPERIMENTAL
Intervention: Mitra™
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dried Blood Spots (DBS)
Number of subjects: 35
Study: 27239902

Group type: EXPERIMENTAL
Intervention: Oral biographical disclosure
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Structured biographical writing
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Daily diary
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study: 23859485

Group type: EXPERIMENTAL
Intervention: Accelerated collagen cross-linking (CXL)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-operative eyes (control)
Number of subjects: 36
Study: 22323576

Group type: EXPERIMENTAL
Intervention: Active nicotine mouth spray (n=318)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Placebo (n=161)
Number of subjects: 479
Study: 19962270

Group type: EXPERIMENTAL
Intervention: Vertical incision
Number of subjects: 88

Group type: COMPARATOR
Intervention: Transverse incision
Number of subjects: 88
Study: 18949838

Group type: EXPERIMENTAL
Intervention: Painful constipation (PC)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: High pain constipation (HPC)
Number of subjects: 231
Study: 15986443

Group type: EXPERIMENTAL
Intervention: Current injectable hormonal contraceptive use
Number of subjects: 5060

Group type: EXPERIMENTAL
Intervention: Current injectable hormonal contraceptive use among women with HPV16 infection
Number of subjects: 5060

Group type: COMPARATOR
Intervention: Former oral contraceptive use
Number of subjects: 5060

Group type: COMPARATOR
Intervention: Oral contraceptive use, Norplant use, history of pregnancy, age at first pregnancy, lifetime numbers of pregnancies and live births
Number of subjects: 5060
Study: 12665083

Group type: EXPERIMENTAL
Intervention: Smokers with repeated quit attempts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smokers (whole group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 0
Study: 10852448

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8654467

Group type: EXPERIMENTAL
Intervention: Bromazepam-containing ondansetron regimen
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ondansetron alone
Number of subjects: 35
Study: 1513608

Group type: EXPERIMENTAL
Intervention: Loracarbef (15‐mg/kg/day oral suspension or 200‐mg capsule taken twice daily for 10 days)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Penicillin VK (20‐mg/kg/day oral suspension or 250‐mg capsule taken four times daily for 10 days)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 233

Group type: COMPARATOR
Intervention: Penicillin VK
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Loracarbef and Penicillin VK
Number of subjects: 233
Study: 6337473

Group type: EXPERIMENTAL
Intervention: Oral erythromycin ethylsuccinate (40 mg/kg/day in divided doses) for five days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 26
Study: 31869340

Group type: EXPERIMENTAL
Intervention: Commonly missed nursing care elements in the perinatal setting.
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Reasons for commonly missed nursing care.
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Factors associated with commonly missed nursing care.
Number of subjects: 422
Study: 29856768

Group type: EXPERIMENTAL
Intervention: Exercise training (supervised training sessions three times weekly and home exercise once weekly)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard maternity care (control group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 55

Group type: COMPARATOR
Intervention: Newborns of normal weight women (n = 20)
Number of subjects: 55
Study: 26813468

Group type: EXPERIMENTAL
Intervention: 2.0 g Hawaiian spirulina daily for three months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24817203

Group type: EXPERIMENTAL
Intervention: Racial/ethnic match with therapist
Number of subjects: 224

Group type: COMPARATOR
Intervention: Racial/ethnic mismatch with therapist
Number of subjects: 224
Study: 21551226

Group type: EXPERIMENTAL
Intervention: Financial hardship
Number of subjects: 431

Group type: COMPARATOR
Intervention: No financial hardship (control group)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Childhood poverty
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Intra-cranial volume
Number of subjects: 431
Study: 19458887

Group type: EXPERIMENTAL
Intervention: Low-drop (LD) exercise group performing single-leg drop-landings from 14 cm
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High-drop (HD) exercise group performing single-leg drop-landings from 28 cm
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 42
Study: 17502530

Group type: EXPERIMENTAL
Intervention: Calcium plus 400 IU of cholecalciferol (vitamin D) daily
Number of subjects: 36282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study: 12804729

Group type: EXPERIMENTAL
Intervention: Niacin ER 1,000 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Niacin ER 2,000 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Niacin ER (both dosages)
Number of subjects: 60
Study: 10744847

Group type: EXPERIMENTAL
Intervention: Interpersonal stress manipulation
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ego-related stress manipulation 1
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ego-related stress manipulation 2
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 9010511

Group type: EXPERIMENTAL
Intervention: Institutional AIDS prevention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control campus
Number of subjects: 0
Study: 1354938

Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg, 3 times daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ibopamine (acute administration)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ibopamine (chronic administration)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ibopamine (acute and chronic administration)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 6423720

Group type: EXPERIMENTAL
Intervention: Ethanol infusion (0.4 g/kg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ethanol infusion (0.8 g/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 19
Study: 30969797

Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zoledronic acid (ZA)
Number of subjects: 0
Study: 28190794

Group type: EXPERIMENTAL
Intervention: BMSC (n = 17)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: BMMC (n = 16)
Number of subjects: 53

Group type: COMPARATOR
Intervention: CTRL (n = 20)
Number of subjects: 53
Study: 25499546

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (retinol palmitate 50,000 IU plus vitamin E 95-126 IU)
Number of subjects: 44984

Group type: COMPARATOR
Intervention: Placebo (vitamin E 95-126 IU)
Number of subjects: 44984
Study: 23820354

Group type: EXPERIMENTAL
Intervention: High fluid intake
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low fluid intake (dehydrated, 1-3% weight loss)
Number of subjects: 40
Study: 21659667

Group type: EXPERIMENTAL
Intervention: Subliminal priming of exercise self-regulatory efficacy beliefs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supraliminal priming of exercise self-regulatory efficacy beliefs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-efficacy priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control prime
Number of subjects: 0
Study: 20141705

Group type: EXPERIMENTAL
Intervention: TAU augmented with brief group cognitive therapy (CT)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 172
Study: 16683683

Group type: EXPERIMENTAL
Intervention: Alert (Jeneric/Pentron) resin composite with a flowable composite liner
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SureFil (Dentsply/Caulk) resin composite with a flowable composite liner
Number of subjects: 50

Group type: COMPARATOR
Intervention: Alert (Jeneric/Pentron) resin composite
Number of subjects: 50

Group type: COMPARATOR
Intervention: SureFil (Dentsply/Caulk) resin composite
Number of subjects: 50
Study: 17205408

Group type: EXPERIMENTAL
Intervention: Virtual colonoscopy
Number of subjects: 48
Study: 10230944

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver in supine position
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver in Trendelenburg position
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined Valsalva maneuver and Trendelenburg position
Number of subjects: 50

Group type: COMPARATOR
Intervention: LIJV CSA less than RIJV
Number of subjects: 50
Study: 8688398

Group type: EXPERIMENTAL
Intervention: Loading dose ritodrine infusion
Number of subjects: 203

Group type: COMPARATOR
Intervention: Conventional schedule of increasing doses of ritodrine
Number of subjects: 203
Study: 2070984

Group type: EXPERIMENTAL
Intervention: Atropine (0.5 mg)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 6409009

Group type: EXPERIMENTAL
Intervention: MMC and 5‐FU (Group A)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: MMC, 5‐FU and OK‐432 (Group B)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 94
Study: 30761568

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (PT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: One session of plaque removal (Control group)
Number of subjects: 82
Study: 30077955

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia (CBT-I)
Number of subjects: 74
Study: 27390130

Group type: EXPERIMENTAL
Intervention: IV→150 mg secukinumab
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: IV→75 mg secukinumab
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study: 24162898

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) group
Number of subjects: 216
Study: 21104100

Group type: EXPERIMENTAL
Intervention: Nanofilled resin composite with intermediary layer of flowable resin composite
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nanofilled resin composite without intermediary layer of flowable resin composite
Number of subjects: 48
Study: 20554627

Group type: EXPERIMENTAL
Intervention: CLU (rs11136000)
Number of subjects: 1829
Study: 18605891

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional surgical therapy
Number of subjects: 18
Study: 15750038

Group type: EXPERIMENTAL
Intervention: Children with OSAS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 10
Study: 12219856

Group type: EXPERIMENTAL
Intervention: Accountability (expectation to explain, justify, and defend one's self-evaluations to an audience)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accountability (as defined above)
Number of subjects: 0
Study: 10505301

Group type: EXPERIMENTAL
Intervention: Cerivastatin 400 micrograms/day
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Cerivastatin 300 micrograms/day
Number of subjects: 349

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Cerivastatin treatment
Number of subjects: 349
Study: 8572787

Group type: EXPERIMENTAL
Intervention: Cooling jacket
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stanford method (saline lavage)
Number of subjects: 20
Study: 2012456

Group type: EXPERIMENTAL
Intervention: 800 mg of aspirin with 64 mg of caffeine
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: 800 mg of aspirin
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 30632140

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 997

Group type: COMPARATOR
Intervention: Ustekinumab 45 mg or 90 mg
Number of subjects: 997

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 997
Study: 28787712

Group type: EXPERIMENTAL
Intervention: Immediate feedback regarding amyloid status
Number of subjects: 618

Group type: COMPARATOR
Intervention: Delayed feedback regarding amyloid status
Number of subjects: 618
Study: 25391306

Group type: EXPERIMENTAL
Intervention: HP + CVVH
Number of subjects: 684

Group type: COMPARATOR
Intervention: HP
Number of subjects: 684
Study: 23497560

Group type: EXPERIMENTAL
Intervention: Shape Up-LD intervention (12 weekly sessions including healthy eating messages, advice on physical activity, and behaviour change techniques)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 21803749

Group type: EXPERIMENTAL
Intervention: Stopping NSAIDs (for a minimum of 5 drug half-lives)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Continuing NSAIDs
Number of subjects: 58
Study: 18976782

Group type: EXPERIMENTAL
Intervention: Clozapine-treated schizophrenia patients
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Unmedicated schizophrenia patients
Number of subjects: 163
Study: 17313721

Group type: EXPERIMENTAL
Intervention: Chocolate milk (500 ml, 900 kJ)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cola (500 ml, 900 kJ)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Chocolate milk
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cola
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Chocolate milk and Cola
Number of subjects: 22
Study: 15369934

Group type: EXPERIMENTAL
Intervention: Pre-emptive antiemetic therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no pre-emptive therapy)
Number of subjects: 25
Study: 11394392

Group type: EXPERIMENTAL
Intervention: Combination of enamel matrix proteins (EMP), bovine porous bone mineral (BPBM), and a bioabsorbable membrane for guided tissue regeneration (GTR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 18
Study: 9721382

Group type: EXPERIMENTAL
Intervention: Questionnaires measuring condom use (varied types)
Number of subjects: 2269

Group type: EXPERIMENTAL
Intervention: 2-week coital logs or past 10 acts
Number of subjects: 2269

Group type: EXPERIMENTAL
Intervention: Always-to-never scales
Number of subjects: 2269

Group type: EXPERIMENTAL
Intervention: Internal consistency of responses
Number of subjects: 2269

Group type: EXPERIMENTAL
Intervention: Future studies
Number of subjects: 2269
Study: 8055123

Group type: EXPERIMENTAL
Intervention: High physical activity (PA) level in women
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: High physical activity (PA) level in men
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group (no radiologic evidence of knee OA)
Number of subjects: 339
Study: 2500361

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 4 x 0.1 mg.day‐1
Number of subjects: 22

Group type: COMPARATOR
Intervention: Inhaled cromoglycate 4 x 2 mg.day‐1
Number of subjects: 22